Tetracyclic Pyridone Compounds Inhibit HBV Replication

The invention targets multiple distinct stages of the HBV life cycle with different compounds in the combination regimen: entry inhibitors block viral attachment, uncoating inhibitors prevent capsid disassembly, polymerase inhibitors block DNA synthesis, and cccDNA transcription inhibitors prevent HBsAg production. This segmented approach addresses each viral replication step separately, reducing the likelihood of resistance development compared to single-target therapies.

The treatment regimen combines multiple compounds with different mechanisms of action into a composite therapeutic approach. This multi-component strategy includes interferon therapy combined with nucleoside-based inhibitors and novel compounds that target cccDNA, creating a synergistic effect that overcomes the limitations of individual treatments and prevents dominance of resistant mutants.

The invention employs compounds that act preliminarily to block viral entry and uncoating before the virus can establish cccDNA reservoirs in hepatocytes. By preventing early steps of infection (attachment and uncoating), the therapy reduces the formation of new cccDNA reservoirs while existing reservoirs are gradually depleted, addressing the root cause rather than just the symptomatic viral load.

The patent introduces novel compounds as intermediaries that specifically target and inhibit cccDNA transcription and HBsAg production. These compounds act as mediators between the cccDNA reservoir and the production of infectious virions, blocking the transcriptional activity of cccDNA and preventing HBsAg synthesis without directly eliminating the cccDNA itself, thereby addressing the persistent reservoir problem.